Table 1.
Rate of Non-Hodgkin Lymphoma Associated With Immunomodulator and Anti-tumor Necrosis Factor (anti-TNF) Treatment
| Baseline US population* | Immunomodulator-treated† | Anti-TNF + immunomodulator-treated | |
|---|---|---|---|
| Rate of lymphoma per 10,000 patient-years | 1.9 | 3.6 | 6.1 |
| Relative risk of anti-TNF + immunomodulator therapy | |||
| Compared to baseline: SIR 3.23 (95% CI 1.5–6.9) | |||
| Compared to immunomodulator alone: SIR 1.7 (95% CI 0.5–7.1) | |||
- CI=
confidence interval;
- SIR=
standardized incidence ratio.
*
Based upon data from the Surveillance Epidemiology End Results registry.
†
Immunomodulator=azathioprine or 6-mercaptopurine.